Current stock page

Catalysts

PTGX Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

PTGXProtagonist Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$130.95−$3.43 (−2.55%)

Latest quote

  • Momentum
    70
  • Value
    72
  • Quality
    81
  • Risk resilience
    70
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 24, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 73/100

Momentum 70/100 and sentiment — before the next covered event.

Recent coverage
4 articles

Updated Nov 15, 2026 · Sentiment 27.92%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 70/100AIQ Edge 9/10 Strong Relative Position
Beat rate
63%
5 of 8 reported periods
Average surprise
+416.7%
Across covered historical reports
Latest result
+0.3%
Nov 5, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 5, 2026—$3.06$3.07+0.3%$249.38M$274.41M
Aug 5, 2026—$2.23$2.29+2.7%$198.66M$213.48M
May 5, 2026—-$0.65$0.05+107.7%$11.7M$56.37M
Feb 25, 2026—-$0.53-$0.69-30.2%$8.74M$7.44M
Nov 6, 2025—-$0.59-$0.62-5.1%$14.92M$4.71M
Aug 6, 2025—-$0.53-$0.55-3.8%$8.43M$5.55M
May 6, 2025—-$0.50-$0.19+62.0%$6.56M$28.32M
Feb 21, 2025—$0.06$1.98+3200.0%$81.01M$170.64M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
14
Buy
12-month analyst target
$176.80
+35.01% versus current price
Based on 14 analyst observations. Targets are estimates, not predictions.
Low target
$160.00
+22.18% vs latest price
Average target
$176.80
+35.01% vs latest price
High target
$190.00
+45.09% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 24, 2027

Next known earnings or reporting date.

EPS estimate-$0.15

Current analyst expectation for the upcoming report.

Revenue estimate$45.42M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score70

Where event reaction would show up first.

AIQ score73/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
14
Average target
$176.80
Target upside
35.01%
Target range
$160.00 - $190.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
1
Negative
0
seekingalpha.com · Oct 25, 2026

Protagonist Therapeutics Stock: Opt-Out Turned A Biotech Royalty Compounder (NASDAQ:PTGX)

Protagonist Therapeutics has evolved into a royalty-driven company with two FDA-approved drugs. Read why PTGX stock is a Buy.

gurufocus.com · Oct 21, 2026

PTGX Maintained by TD Cowen -- Price Target Raised to $160

On October 23, 2023, TD Cowen maintained a 'Buy' rating on Protagonist Therapeutics (PTGX), adjusting the price target from $155.00 to $160.00, reflecting a 3.2

insidermonkey.com · Sep 6, 2026

Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status

On August 5, Protagonist Therapeutics (NASDAQ:PTGX) reported second-quarter 2026 results that flipped the company from red ink to a $162.8 million profit, or $2.29 per diluted share, compared with a $...

finance.yahoo.com · Sep 4, 2026

MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?

U.S. Food and Drug Administration approval of MIMRYLO, or rusfertide, for erythrocytosis in adults with polycythemia vera triggered $275 million in payments to Protagonist Therapeutics, Inc. (NASDAQ:PTGX). The amount consists of an additional $200 million opt-out fee and a separate $75 million approval milestone. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) chose royalties over the original 50:50 U.S. […]

Open full news and sentiment

PTGX Catalysts FAQ

What are the next catalysts for PTGX stock?

PTGX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move PTGX stock?

Upcoming events that could move PTGX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could PTGX's next earnings report affect the stock?

PTGX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive PTGX stock higher?

PTGX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt PTGX stock?

PTGX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.